Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
11:15am, Wednesday, 10'th Nov 2021
An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
Cassava Sciences Stock: Top Contender For A Continued Short Squeeze
05:44am, Wednesday, 10'th Nov 2021
Cassava Sciences Stock: Top Contender For A Continued Short Squeeze
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
11:51am, Tuesday, 09'th Nov 2021
Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. The post Cassava Sciences Needs Time and Data to Prove Itself B
Cassava Is a Sell After Accusations of Data Manipulation
09:16am, Tuesday, 09'th Nov 2021
After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. The post Cassava Is a Sell After Accusations of Data Manip
Cassava Sciences' Hypothesis Raises Doubts
06:43pm, Monday, 08'th Nov 2021
Central to Cassava's hypothesis requires amyloid beta-42 to induce an altered conformation of structural protein filamin A and that sumifilam restores altered filmin A back to its native state. Resear
4 Top Biotech Stocks To Watch This Week
05:30pm, Monday, 08'th Nov 2021
Check out these biotech stocks that could prove to be valuable additions to your portfolio.
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
04:48pm, Monday, 08'th Nov 2021
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
Cassava Sciences: A Close Look
07:44am, Saturday, 06'th Nov 2021
On Nov 4, Cassava Sciences issued a PR which headline reads, 'Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' And the sub-
Stocks Heading Into Holiday Season With Record Highs
04:12pm, Friday, 05'th Nov 2021
Stocks continued their run of near daily record highs heading into November, as investors digested a slew of economic updates and earnings reports.
Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?
05:53am, Friday, 05'th Nov 2021
Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.
Cassava Sciences (SAVA) Stock: Why The Price Surged Today
10:27pm, Thursday, 04'th Nov 2021
The stock price of Cassava Sciences Inc (NASDAQ: SAVA) surged 48.96% today. This is why it happened.
Why Did Cassava Sciences Stock Jump 49% Today?
05:24pm, Thursday, 04'th Nov 2021
Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating A
Cassava Sciences Stock Surges on Alzheimer's Article Update
03:49pm, Thursday, 04'th Nov 2021
Cassava Sciences Inc (NASDAQ:SAVA) is soaring today, up 46.1% to trade at $82.80 at last glance, after the company said the Journal of Neuroscience found no evidence of data manipulation in its 2012
Cassava Sciences: Major Hit To The Bears
03:11pm, Thursday, 04'th Nov 2021
No evidence of data manipulation.
Why Cassava Sciences Shares Are Rising
02:04pm, Thursday, 04'th Nov 2021
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company technical paper. "I've
